PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27437459-1	2014	Lornoxicam is a selective cyclooxygenase-1 and cyclooxygenase-2 inhibitor that exhibits anti-inflammatory, analgesic, and antipyretic activities.	lornoxicam	0-10	prostaglandin-endoperoxide synthase 1	Homo sapiens	26-42
25872171-1	2015	OBJECTIVES: To assess the effects of the cyclooxygenase-1/cyclooxygenase-2 inhibitor lornoxicam on systemic complications in patients with acute pancreatitis, Toll-like receptor (TLR)2 and TLR4 messenger RNA expression, and cytokine secretion (IL-6, IL-8, tumor necrosis factor-alpha).	lornoxicam	85-95	prostaglandin-endoperoxide synthase 2	Homo sapiens	58-74
25872171-1	2015	OBJECTIVES: To assess the effects of the cyclooxygenase-1/cyclooxygenase-2 inhibitor lornoxicam on systemic complications in patients with acute pancreatitis, Toll-like receptor (TLR)2 and TLR4 messenger RNA expression, and cytokine secretion (IL-6, IL-8, tumor necrosis factor-alpha).	lornoxicam	85-95	toll like receptor 2	Homo sapiens	179-184
25872171-8	2015	Relative TLR2 expression and cytokine production were significantly reduced in patients receiving lornoxicam versus standard therapy.	lornoxicam	98-108	toll like receptor 2	Homo sapiens	9-13
25872171-9	2015	CONCLUSIONS: The use of lornoxicam at the onset of acute pancreatitis decreased TLR2 and TLR4 expression and the production of proinflammatory cytokines, thereby reducing the risk of systemic complications and mortality.	lornoxicam	24-34	toll like receptor 4	Homo sapiens	89-93
25403387-0	2014	Effect of lornoxicam therapy on expression of TLR2 and TLR4 mRNA during systemic complications of acute pancreatitis.	lornoxicam	10-20	toll like receptor 2	Homo sapiens	46-50
25403387-0	2014	Effect of lornoxicam therapy on expression of TLR2 and TLR4 mRNA during systemic complications of acute pancreatitis.	lornoxicam	10-20	toll like receptor 4	Homo sapiens	55-59
25403387-6	2014	We studied mRNA expression of TLR2 and TLR4 in the peripheral blood mononuclear cells from the patients with acute pancreatitis and showed a decrease in the examined parameters associated with lornoxicam treatment.	lornoxicam	193-203	toll like receptor 2	Homo sapiens	30-34
25403387-6	2014	We studied mRNA expression of TLR2 and TLR4 in the peripheral blood mononuclear cells from the patients with acute pancreatitis and showed a decrease in the examined parameters associated with lornoxicam treatment.	lornoxicam	193-203	toll like receptor 4	Homo sapiens	39-43
27086708-0	2016	Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain.	lornoxicam	42-52	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	20-25
27086708-0	2016	Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain.	lornoxicam	42-52	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	26-31
27437459-1	2014	Lornoxicam is a selective cyclooxygenase-1 and cyclooxygenase-2 inhibitor that exhibits anti-inflammatory, analgesic, and antipyretic activities.	lornoxicam	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	47-63
21049628-1	2010	OBJECTIVE: To explore the role of Tong Mai Tang & Lornoxicam on the serum concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin (IL-6) , D-dipolymer( D-Di), Platelet count (PLC) in treatment of femoral shaft fracture among period surgery time.	lornoxicam	54-64	tumor necrosis factor	Homo sapiens	96-123
25416223-4	2014	Previous injection of Xefocam with 0,4 mg/kg dose decreased levels of DNMT3a and 3b (25 and 24% respectively).	lornoxicam	22-29	DNA methyltransferase 3 alpha	Rattus norvegicus	70-83
24672701-14	2014	IL-6 levels of lornoxicam group were statistical significant lower at 1st postoperative day compared to them of control group (113+-49 and 177+-20 respectively, P=0.008).	lornoxicam	15-25	interleukin 6	Homo sapiens	0-4
21726410-0	2011	Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.	lornoxicam	64-74	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	15-21
21726410-1	2011	Lornoxicam is extensively metabolized by CYP2C9, and a CYP2C9*13 is one of the principal variant alleles in East Asian populations.	lornoxicam	0-10	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	41-47
21726410-1	2011	Lornoxicam is extensively metabolized by CYP2C9, and a CYP2C9*13 is one of the principal variant alleles in East Asian populations.	lornoxicam	0-10	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	55-61
21726410-2	2011	The aim of this study was to evaluate the effects of CYP2C9*1/*13 on the pharmacokinetic parameters of lornoxicam in healthy individuals.	lornoxicam	103-113	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	53-59
21726410-5	2011	In individuals with CYP2C9*1/*13, lornoxicam had a higher C(max) (p < 0.001), a longer half-life (p < 0.001), a lower oral clearance (p < 0.001) and a higher area under the plasma concentration-time curve from zero to infinity (AUC(inf) ) than in CYP2C9*1/*1 individuals (p < 0.001).	lornoxicam	34-44	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	20-26
21726410-5	2011	In individuals with CYP2C9*1/*13, lornoxicam had a higher C(max) (p < 0.001), a longer half-life (p < 0.001), a lower oral clearance (p < 0.001) and a higher area under the plasma concentration-time curve from zero to infinity (AUC(inf) ) than in CYP2C9*1/*1 individuals (p < 0.001).	lornoxicam	34-44	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	256-262
21726410-7	2011	The half-life, oral clearance and AUC(inf) of lornoxicam were similar in individuals with CYP2C9*1/*13 and those with CYP2C9*1/*3.	lornoxicam	46-56	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	90-96
21726410-9	2011	A CYP2C9*1/*13 genotype markedly reduced the conversion of lornoxicam to 5"-hydroxylornoxicam, to a similar extent as that observed with the CYP2C9*1/*3 genotype.	lornoxicam	59-69	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	2-8
21726410-9	2011	A CYP2C9*1/*13 genotype markedly reduced the conversion of lornoxicam to 5"-hydroxylornoxicam, to a similar extent as that observed with the CYP2C9*1/*3 genotype.	lornoxicam	59-69	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	141-147
20924657-1	2011	The interaction between an anti-inflammatory drug, lornoxicam (LXM) and protein (human serum albumin and bovine serum albumin) was studied by spectroscopic techniques (Fluorescence, synchronous, FT-IR, UV-vis absorption and circular dichroism).	lornoxicam	51-61	albumin	Homo sapiens	87-100
20924657-1	2011	The interaction between an anti-inflammatory drug, lornoxicam (LXM) and protein (human serum albumin and bovine serum albumin) was studied by spectroscopic techniques (Fluorescence, synchronous, FT-IR, UV-vis absorption and circular dichroism).	lornoxicam	51-61	albumin	Homo sapiens	112-125
20813681-10	2010	CONCLUSIONS: Preoperative intravenous LOR injection may increase serum RANTES level and decrease MCP-1 and SDF-1alpha expressions to effectively relieve the perioperative immune disorders caused by TAH, and the effect is more potent at the dose of 16 mg.	lornoxicam	38-41	C-C motif chemokine ligand 5	Homo sapiens	71-77
20813681-10	2010	CONCLUSIONS: Preoperative intravenous LOR injection may increase serum RANTES level and decrease MCP-1 and SDF-1alpha expressions to effectively relieve the perioperative immune disorders caused by TAH, and the effect is more potent at the dose of 16 mg.	lornoxicam	38-41	C-C motif chemokine ligand 2	Homo sapiens	97-102
21049628-1	2010	OBJECTIVE: To explore the role of Tong Mai Tang & Lornoxicam on the serum concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin (IL-6) , D-dipolymer( D-Di), Platelet count (PLC) in treatment of femoral shaft fracture among period surgery time.	lornoxicam	54-64	tumor necrosis factor	Homo sapiens	125-134
21049628-17	2010	CONCLUSION: The serum concentrations of TNF-alpha, IL-6, D-Di and PLC level were significantly increased in peroperative period, These results seem to indicate that the Tong Mai Decoctions & Lornoxicam may play an important role in inhibiting the release of TNF-alpha, IL-6, D-Di and PLC into the blood stream and decreasing the incunabula complication at early traumatic stage.	lornoxicam	195-205	tumor necrosis factor	Homo sapiens	40-49
21049628-17	2010	CONCLUSION: The serum concentrations of TNF-alpha, IL-6, D-Di and PLC level were significantly increased in peroperative period, These results seem to indicate that the Tong Mai Decoctions & Lornoxicam may play an important role in inhibiting the release of TNF-alpha, IL-6, D-Di and PLC into the blood stream and decreasing the incunabula complication at early traumatic stage.	lornoxicam	195-205	interleukin 6	Homo sapiens	51-55
21049628-17	2010	CONCLUSION: The serum concentrations of TNF-alpha, IL-6, D-Di and PLC level were significantly increased in peroperative period, These results seem to indicate that the Tong Mai Decoctions & Lornoxicam may play an important role in inhibiting the release of TNF-alpha, IL-6, D-Di and PLC into the blood stream and decreasing the incunabula complication at early traumatic stage.	lornoxicam	195-205	tumor necrosis factor	Homo sapiens	262-271
21049628-17	2010	CONCLUSION: The serum concentrations of TNF-alpha, IL-6, D-Di and PLC level were significantly increased in peroperative period, These results seem to indicate that the Tong Mai Decoctions & Lornoxicam may play an important role in inhibiting the release of TNF-alpha, IL-6, D-Di and PLC into the blood stream and decreasing the incunabula complication at early traumatic stage.	lornoxicam	195-205	interleukin 6	Homo sapiens	273-277
21516735-5	2010	RESULTS: The lornoxicam group exhibited a significant reduction in CRP and a decrease in IL-6.	lornoxicam	13-23	C-reactive protein	Homo sapiens	67-70
21516735-5	2010	RESULTS: The lornoxicam group exhibited a significant reduction in CRP and a decrease in IL-6.	lornoxicam	13-23	interleukin 6	Homo sapiens	89-93
19548782-5	2009	The six analgesics dose-dependently decreased in vitro hPON1 activity, with IC(50) values for lornoxicam, indomethacin, tenoxicam, diclofenac sodium, ketoprofen and lincomycine of 0.136, 0.195, 0.340, 1.639, 6.23 and 9.638 mM, respectively.	lornoxicam	94-104	paraoxonase 1	Homo sapiens	55-60
19966527-7	2009	Following TAH, the serum levels of RANTES were reduced in the untreated patients, but were significantly higher in the patients treated with LOR.	lornoxicam	141-144	C-C motif chemokine ligand 5	Homo sapiens	35-41
19966527-8	2009	In addition, the levels of MCP-1 and SDF-1alpha were significantly elevated in the untreated patients, but were significantly lower in the patients treated with LOR.	lornoxicam	161-164	C-C motif chemokine ligand 2	Homo sapiens	27-32
19821419-1	2009	BACKGROUND: Lornoxicam is one of the oxicam class of non-steroidal anti-inflammatory drugs (NSAIDs), producing analgesic and antipyretic effects in part through the non-selective inhibition of cyclo-oxygenase-1 and -2.	lornoxicam	12-22	prostaglandin-endoperoxide synthase 1	Homo sapiens	193-217
19832818-7	2009	Significant differences in PID between LNX and placebo were seen in the time interval 3-8 h after the first dose including PID(0-6 h) (p = 0.015).	lornoxicam	39-42	metastasis associated 1 family member 2	Homo sapiens	27-30
19832818-7	2009	Significant differences in PID between LNX and placebo were seen in the time interval 3-8 h after the first dose including PID(0-6 h) (p = 0.015).	lornoxicam	39-42	metastasis associated 1 family member 2	Homo sapiens	123-126
19422321-1	2009	Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.	lornoxicam	231-241	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	17-23
19547717-0	2009	Lornoxicam suppresses recurrent herpetic stromal keratitis through down-regulation of nuclear factor-kappaB: an experimental study in mice.	lornoxicam	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	86-107
19547717-1	2009	PURPOSE: We designed the current study to determine the protective effects of lornoxicam, a cyclooxygenase (COX) inhibitor, on recurrent herpetic stromal keratitis (HSK) and the nuclear factor-kappaB (NF-kappaB)-mediated mechanism in mice.	lornoxicam	78-88	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	178-199
19547717-1	2009	PURPOSE: We designed the current study to determine the protective effects of lornoxicam, a cyclooxygenase (COX) inhibitor, on recurrent herpetic stromal keratitis (HSK) and the nuclear factor-kappaB (NF-kappaB)-mediated mechanism in mice.	lornoxicam	78-88	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	201-210
19547717-8	2009	Immunohistochemical staining and an electrophoretic mobility shift assay were performed to evaluate the effect of lornoxicam on NF-kappaB activation in the corneal tissues.	lornoxicam	114-124	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	128-137
19547717-11	2009	Lornoxicam treatment significantly decreased the incidence of recurrent HSK, attenuated the corneal opacity scores, and also effectively suppressed both NF-kappaB activation and TNF-alpha expression in biological analysis.	lornoxicam	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	153-162
19547717-11	2009	Lornoxicam treatment significantly decreased the incidence of recurrent HSK, attenuated the corneal opacity scores, and also effectively suppressed both NF-kappaB activation and TNF-alpha expression in biological analysis.	lornoxicam	0-10	tumor necrosis factor	Mus musculus	178-187
19547717-12	2009	Histopathology examination revealed a reduced immunostaining positive cell density for NF-kappaB in the cornea from lornoxicam-treated mice as well as a diminished inflammatory response.	lornoxicam	116-126	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	87-96
19547717-13	2009	CONCLUSIONS: Lornoxicam exerts protective effects against HSK, presumably through the down-regulation of NF-kappaB activation.	lornoxicam	13-23	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	105-114
19422321-1	2009	Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.	lornoxicam	231-241	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	28-34
19422321-1	2009	Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.	lornoxicam	231-241	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	84-90
19422321-1	2009	Polymorphisms in CYP2C8 and CYP2C9 are common in all the human populations and many CYP2C8 and CYP2C9 gene variations cause decreased enzyme activity towards the NSAIDs aceclofenac, celecoxib, diclofenac, ibuprofen, indomethazine, lornoxicam, meloxicam, naproxen, piroxicam, tenoxicam and valdecoxib.	lornoxicam	231-241	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	95-101
18369073-0	2008	Lornoxicam protects mouse cornea from UVB-induced damage via inhibition of NF-{kappa}B activation.	lornoxicam	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	75-86
24692827-3	2009	OBJECTIVE: The aim of this prospective, randomized, controlled study was to observe the effects of preemptive IV lornoxicam treatment on the analgesic efficacy of PCEA with morphine and on the expression of monocyte chemotactic protein-1 (MCP-1) and stromal cell-derived factor-1alpha (SDF-1alpha) in women undergoing hysterectomy.	lornoxicam	113-123	chemokine (C-C motif) ligand 2	Mus musculus	207-237
24692827-3	2009	OBJECTIVE: The aim of this prospective, randomized, controlled study was to observe the effects of preemptive IV lornoxicam treatment on the analgesic efficacy of PCEA with morphine and on the expression of monocyte chemotactic protein-1 (MCP-1) and stromal cell-derived factor-1alpha (SDF-1alpha) in women undergoing hysterectomy.	lornoxicam	113-123	chemokine (C-C motif) ligand 2	Mus musculus	239-244
24692827-12	2009	CONCLUSION: Preemptive IV lornoxicam treatment was associated with attenuation of the plasma concentrations of MCP-1 and SDF-1alpha immediately after and 24 hours after hysterectomy and was associated with more rapid resolution to near-baseline concentrations of both cytokines in these patients compared with controls; however, it was not associated with significantly reducing epidural morphine consumption.	lornoxicam	26-36	C-C motif chemokine ligand 2	Homo sapiens	111-116
24692832-2	2009	OBJECTIVE: The aim of this study was to compare the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult Indian patients with OA of the hip or knee.	lornoxicam	86-96	BH3 interacting domain death agonist	Homo sapiens	102-105
18434268-16	2008	Group PRE also demonstrated a weakly significant reduction in analgesic consumption of tramadol postoperatively compared to Groups POST and C. CONCLUSION: Lornoxicam administered preemptively appears to improve the quality of postoperative analgesia and leads to reduced consumption of tramadol postoperatively in patients undergoing major abdominal operations.	lornoxicam	155-165	solute carrier family 35 member G1	Homo sapiens	131-135
18468391-4	2008	Then, the influence of indometacin, lornoxicam and celecoxib on the expression of occludin, ZO-1, ICAM-1 and vWF of the two cell lines and HUVEC was analysed by cell ELISA.	lornoxicam	36-46	occludin	Homo sapiens	82-90
18369073-10	2008	Lornoxicam treatment significantly suppressed UVB-induced increases in NF-kappaB-DNA binding and TNF-alpha expression.	lornoxicam	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	71-80
18369073-10	2008	Lornoxicam treatment significantly suppressed UVB-induced increases in NF-kappaB-DNA binding and TNF-alpha expression.	lornoxicam	0-10	tumor necrosis factor	Mus musculus	97-106
18369073-11	2008	CONCLUSION: Lornoxicam treatment attenuates UVB-induced corneal damage via inhibition of NF-kappaB activation.	lornoxicam	12-22	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	89-98
16740353-4	2006	CYP2C9*13, firstly identified by some of the present authors in a Chinese poor metabolizer of lornoxicam, is characterized by mutation encoding Leu90Pro substitution.	lornoxicam	94-104	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
18991469-1	2008	OBJECTIVE: The aim of this study was to evaluate the analgesic efficacy and time to onset of effect of the lornoxicam quick-release (LNX-QR) tablet compared with the standard-release tablet (LNX-ST).	lornoxicam	107-117	ligand of numb-protein X 1	Homo sapiens	133-136
18390209-1	2008	OBJECTIVE: The objective of this study was to investigate an antinociceptive effect of preemptive intrathecal lornoxicam on behavior and expression of c-Fos protein in the spinal cord of the formalin hurting rats.	lornoxicam	110-120	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	151-156
18390209-16	2008	CONCLUSION: Pre-intrathacal lornoxicam can successfully inhibit nociceptive behavior and c-Fos expression in spinal dorsal horn of formalin test rats.	lornoxicam	28-38	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	89-94
16740353-5	2006	Kinetic experiments show that CYP2C9*13 has less catalytic activity in elimination of diclofenac and lornoxicam in vitro.	lornoxicam	101-111	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	30-36
16740353-7	2006	The structure change caused by Leu90Pro replacement is revealed and used to explain the dramatic decrease of the enzymatic activity in clearance of the two CYP2C9 substrates: diclofenac and lornoxicam.	lornoxicam	190-200	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	156-162
16118328-8	2005	In contrast, CYP2C9 genotype is expected to impact the clearance of ibuprofen, indomethacin, flurbiprofen, celecoxib, valdecoxib, lornoxicam, tenoxicam, meloxicam, and piroxicam.	lornoxicam	130-140	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	13-19
17017983-11	2006	In contrast lornoxicam and meloxicam, which demonstrated activity against COX-2, have revealed smaller partition capacity in liposomes/water systems together with a higher ability to change the membrane fluidity and surface potential.	lornoxicam	12-22	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	74-79
17022718-11	2006	The risk for digestive hemorrhage associated with the CYP2C9 genotype is particularly relevant when using aceclofenac, celecoxib, diclofenac, ibuprofen, indomethacin, lornoxicam, piroxicam, or naproxen.	lornoxicam	167-177	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	54-60
16342679-0	2005	[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects].	lornoxicam	105-115	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	27-33
16308280-2	2005	CYP2C9*13 is an allele identified in a Chinese poor metabolizer of lornoxicam which has a Leu90Pro amino acid substitution.	lornoxicam	67-77	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6
16342679-0	2005	[Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects].	lornoxicam	105-115	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	49-55
16342679-1	2005	AIM: To investigate the impact of CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam.	lornoxicam	90-100	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	34-40
16342679-8	2005	After a single oral dose of 8 mg lornoxicam, C(max) was (1.54 +/- 0.24) mg x L(-1) in CYP2C9 * 1/ * 3 subjects and (1.19 +/- 0.37) mg x L(-1) in * 1/ * 1 subjects.	lornoxicam	33-43	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	86-92
16342679-12	2005	CONCLUSION: CYP2C9 * 3 greatly affects both the pharmacokinetic profiles of glibenclamide and lornoxicam.	lornoxicam	94-104	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	12-18
16342679-13	2005	The elimination of these drugs significantly decreased in subjects with CYP2C9 * 1/ * 3 genotype, especially lornoxicam.	lornoxicam	109-119	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	72-78
15764711-0	2005	Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans.	lornoxicam	78-88	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	8-14
15764711-0	2005	Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans.	lornoxicam	78-88	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	33-39
15764711-0	2005	Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans.	lornoxicam	78-88	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	33-39
15764711-2	2005	Recently, we identified a new CYP2C9 allele with a Leu90Pro mutation in a Chinese poor metabolizer of lornoxicam [Si D, Guo Y, Zhang Y, Yang L, Zhou H, and Zhong D (2004) Pharmacogenetics 14:465-469].	lornoxicam	102-112	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	30-36
15764711-4	2005	To examine enzymatic activity of the CYP2C9*13 allele, kinetic parameters for lornoxicam 5"-hydroxylation were determined in COS-7 cells transiently transfected with pcDNA3.1 plasmids carrying wild-type CYP2C9*1, variant CYP2C9*3, and CYP2C9*13 cDNA.	lornoxicam	78-88	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	37-43
15764711-8	2005	In a subsequent clinical study, the AUC of lornoxicam was increased by 1.9-fold and its oral clearance (CL/F) decreased by 44% in three CYP2C9*1/*13 subjects, compared with CYP2C9*1/*1 individuals.	lornoxicam	43-53	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	136-142
15606435-0	2005	Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype.	lornoxicam	0-10	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	43-62
15606435-1	2005	AIMS: To investigate the pharmacokinetics of lornoxicam and the relationship with CYP2C9 polymorphism in healthy Chinese subjects.	lornoxicam	45-55	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	82-88
15606435-5	2005	RESULTS: Of the 18 subjects, one subject was found to be a very poor metabolizer of lornoxicam with a long t(1/2) of 106 h, a low CL/F of 0.71 ml min(-1), and a high AUC(0-infinity) of 187.6 microg ml(-1) h. Genotyping studies revealed that this subject was heterozygous for CYP2C9*3 and a new variant CYP2C9 allele.	lornoxicam	84-94	CD59 molecule (CD59 blood group)	Homo sapiens	146-152
15606435-5	2005	RESULTS: Of the 18 subjects, one subject was found to be a very poor metabolizer of lornoxicam with a long t(1/2) of 106 h, a low CL/F of 0.71 ml min(-1), and a high AUC(0-infinity) of 187.6 microg ml(-1) h. Genotyping studies revealed that this subject was heterozygous for CYP2C9*3 and a new variant CYP2C9 allele.	lornoxicam	84-94	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	275-281
15606435-5	2005	RESULTS: Of the 18 subjects, one subject was found to be a very poor metabolizer of lornoxicam with a long t(1/2) of 106 h, a low CL/F of 0.71 ml min(-1), and a high AUC(0-infinity) of 187.6 microg ml(-1) h. Genotyping studies revealed that this subject was heterozygous for CYP2C9*3 and a new variant CYP2C9 allele.	lornoxicam	84-94	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	302-308
15606435-8	2005	CONCLUSIONS: The results show that the pharmacokinetics of lornoxicam are dependent on CYP2C9 polymorphism.	lornoxicam	59-69	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	87-93
15606435-9	2005	In particular, the presence of the CYP2C9*3 allele impairs the oral clearance of lornoxicam.	lornoxicam	81-91	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	35-41
14709614-0	2004	Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5"-hydroxylation.	lornoxicam	70-80	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	19-25
15226678-1	2004	OBJECTIVES: Cytochrome P450 (CYP) 2C9 metabolizes about 16% of drugs in current clinical use, including lornoxicam and tolbutamide.	lornoxicam	104-114	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	12-37
15041603-0	2004	Acetylsalicylic acid, diclofenac, and lornoxicam, but not rofecoxib, affect platelet CD 62 expression.	lornoxicam	38-48	selectin P	Homo sapiens	85-90
17516707-3	2004	Lornoxicam is a strong analgesic and anti-inflammatory NSAID with balanced cyclo-oxygenase (COX)-1/COX-2 inhibition and excellent tolerability.	lornoxicam	0-10	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	75-98
17516707-3	2004	Lornoxicam is a strong analgesic and anti-inflammatory NSAID with balanced cyclo-oxygenase (COX)-1/COX-2 inhibition and excellent tolerability.	lornoxicam	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	99-104
15041603-6	2004	Aspirin, diclofenac, and lornoxicam had a significant effect on arachidonic acid and collagen-induced CD 62 P expression in platelets, whereas rofecoxib did not show this effect.	lornoxicam	25-35	selectin P	Homo sapiens	102-109
14709614-0	2004	Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5"-hydroxylation.	lornoxicam	70-80	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	44-50
14709614-0	2004	Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5"-hydroxylation.	lornoxicam	70-80	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	44-50
14709614-1	2004	The effects of allelic variants of CYP2C9 (CYP2C9*2 and CYP2C9*3) on lornoxicam 5"-hydroxylation were studied using the corresponding variant protein expressed in baculovirus-infected insect cells and human liver microsomes of known genotypes of CYP2C9.	lornoxicam	69-79	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	35-41
14709614-1	2004	The effects of allelic variants of CYP2C9 (CYP2C9*2 and CYP2C9*3) on lornoxicam 5"-hydroxylation were studied using the corresponding variant protein expressed in baculovirus-infected insect cells and human liver microsomes of known genotypes of CYP2C9.	lornoxicam	69-79	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	43-49
14709614-1	2004	The effects of allelic variants of CYP2C9 (CYP2C9*2 and CYP2C9*3) on lornoxicam 5"-hydroxylation were studied using the corresponding variant protein expressed in baculovirus-infected insect cells and human liver microsomes of known genotypes of CYP2C9.	lornoxicam	69-79	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	43-49
14709614-1	2004	The effects of allelic variants of CYP2C9 (CYP2C9*2 and CYP2C9*3) on lornoxicam 5"-hydroxylation were studied using the corresponding variant protein expressed in baculovirus-infected insect cells and human liver microsomes of known genotypes of CYP2C9.	lornoxicam	69-79	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	43-49
14709614-2	2004	The results of the baculovirus expression system showed that CYP2C9.3 gives higher K(m) and lower V(max) values for lornoxicam 5"-hydroxylation than does CYP2C9.1.	lornoxicam	116-126	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	61-67
14709614-8	2004	In conclusion, this study showed that lornoxicam 5"-hydroxylation via CYP2C9 was markedly decreased by the substitution of Ile359Leu (CYP2C9.3), whereas the effect of the substitution of Arg144Cys (CYP2C9.2) was nonexistent or negligible.	lornoxicam	38-48	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	70-76
14709614-8	2004	In conclusion, this study showed that lornoxicam 5"-hydroxylation via CYP2C9 was markedly decreased by the substitution of Ile359Leu (CYP2C9.3), whereas the effect of the substitution of Arg144Cys (CYP2C9.2) was nonexistent or negligible.	lornoxicam	38-48	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	134-140
14709614-8	2004	In conclusion, this study showed that lornoxicam 5"-hydroxylation via CYP2C9 was markedly decreased by the substitution of Ile359Leu (CYP2C9.3), whereas the effect of the substitution of Arg144Cys (CYP2C9.2) was nonexistent or negligible.	lornoxicam	38-48	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	134-140
14709614-9	2004	Additional in vivo studies are required to confirm that individuals with homologous CYP2C9*3 allele exhibit impaired lornoxicam clearance.	lornoxicam	117-127	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	84-90
12649700-0	2003	[Safety of lornoxicam in G-6-PDH deficiency].	lornoxicam	11-21	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	25-32
12454020-6	2003	Importantly, we show that the anti-invasive effect of Cltx on glioma cells can be explained by its interactions with MMP-2.	lornoxicam	54-58	matrix metallopeptidase 2	Homo sapiens	117-122
12454020-7	2003	Cltx exerts a dual effect on MMP-2: it inhibits the enzymatic activity of MMP-2 and causes a reduction in the surface expression of MMP-2.	lornoxicam	0-4	matrix metallopeptidase 2	Homo sapiens	29-34
12454020-7	2003	Cltx exerts a dual effect on MMP-2: it inhibits the enzymatic activity of MMP-2 and causes a reduction in the surface expression of MMP-2.	lornoxicam	0-4	matrix metallopeptidase 2	Homo sapiens	74-79
12454020-7	2003	Cltx exerts a dual effect on MMP-2: it inhibits the enzymatic activity of MMP-2 and causes a reduction in the surface expression of MMP-2.	lornoxicam	0-4	matrix metallopeptidase 2	Homo sapiens	74-79
12454020-8	2003	These findings suggest that Cltx is a specific MMP-2 inhibitor with significant therapeutic potential for gliomas and other diseases that invoke the activity of MMP-2.	lornoxicam	28-32	matrix metallopeptidase 2	Homo sapiens	47-52
12454020-8	2003	These findings suggest that Cltx is a specific MMP-2 inhibitor with significant therapeutic potential for gliomas and other diseases that invoke the activity of MMP-2.	lornoxicam	28-32	matrix metallopeptidase 2	Homo sapiens	161-166
12454020-5	2003	We demonstrate that Cltx specifically and selectively interacts with MMP-2 isoforms, but not with MMP-1, -3, and -9, which are also expressed in malignant glioma cells.	lornoxicam	20-24	matrix metallopeptidase 2	Homo sapiens	69-74
12649700-1	2003	OBJECTIVE: To assess the safety of lornoxicam in subjects with G-6-PDH deficiency.	lornoxicam	35-45	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	63-70
12649700-2	2003	METHODS: Open controlled 2-week in vivo study on lornoxicam 8 mg bid in subjects with G-6-PDH deficiency suffering from rheumatic diseases.	lornoxicam	49-59	BH3 interacting domain death agonist	Homo sapiens	65-68
12649700-2	2003	METHODS: Open controlled 2-week in vivo study on lornoxicam 8 mg bid in subjects with G-6-PDH deficiency suffering from rheumatic diseases.	lornoxicam	49-59	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	86-93
12649700-5	2003	CONCLUSIONS: Lornoxicam caused no RBC damage and evidenced favourable safety in subjects with G-6-PDH deficiency, suffering from rheumatic diseases.	lornoxicam	13-23	hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	Homo sapiens	94-101
8857077-0	1996	Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam.	lornoxicam	66-76	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	31-37
9495582-0	1998	Dose-related anti-inflammatory/analgesic effects of lornoxicam: a spinal c-Fos protein study in the rat.	lornoxicam	52-62	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	73-78
9495582-3	1998	RESULTS: Lornoxicam dose-relatedly reduced both the carrageenan evoked oedema (r=0.63 and r=0.53 for paw and ankle diameter respectively; p<0.001 for both) and total number of spinal c-Fos-LI neurons (r=0.79; p<0.001), with the strongest effect corresponding to a 75 +/- 2% reduction of the number of c-Fos-LI neurons (p<0.001) for the highest dose (9 mg/kg), and a 45 +/- 3% reduction (p<0.001) for the low dose of 0.3 mg/kg.	lornoxicam	9-19	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	186-191
9495582-3	1998	RESULTS: Lornoxicam dose-relatedly reduced both the carrageenan evoked oedema (r=0.63 and r=0.53 for paw and ankle diameter respectively; p<0.001 for both) and total number of spinal c-Fos-LI neurons (r=0.79; p<0.001), with the strongest effect corresponding to a 75 +/- 2% reduction of the number of c-Fos-LI neurons (p<0.001) for the highest dose (9 mg/kg), and a 45 +/- 3% reduction (p<0.001) for the low dose of 0.3 mg/kg.	lornoxicam	9-19	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	307-312
9495582-5	1998	CONCLUSIONS: Our results demonstrate that lornoxicam reduces in parallel both the carrageenan-evoked oedema and spinal c-Fos expression, with clear evidence for a potent effect of low doses of lornoxicam.	lornoxicam	42-52	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	119-124
9495582-5	1998	CONCLUSIONS: Our results demonstrate that lornoxicam reduces in parallel both the carrageenan-evoked oedema and spinal c-Fos expression, with clear evidence for a potent effect of low doses of lornoxicam.	lornoxicam	193-203	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	119-124
9495582-6	1998	Correlated reductions in c-Fos expression and paw oedema suggest a predominantly peripheral site of action of lornoxicam.	lornoxicam	110-120	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	25-30
10640513-11	2000	The degree of pharmacokinetic interactions exhibited by oral anticoagulants and lornoxicam is dependent on the respective contribution of CYP2C9 to their total clearance.	lornoxicam	80-90	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	138-144
10450786-0	1999	The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro.	lornoxicam	20-30	nitric oxide synthase 2	Homo sapiens	67-98
10450786-0	1999	The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro.	lornoxicam	20-30	nitric oxide synthase 2	Homo sapiens	100-104
10450786-1	1999	OBJECTIVE: To investigate anti-inflammatory effects of lornoxicam in vitro on COX-1/COX-2, on NO formation from iNOS and on the formation of the pro-inflammatory cytokines TNF-alpha, IL-1beta, IL-6, and IL-8.	lornoxicam	55-65	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	78-83
10450786-1	1999	OBJECTIVE: To investigate anti-inflammatory effects of lornoxicam in vitro on COX-1/COX-2, on NO formation from iNOS and on the formation of the pro-inflammatory cytokines TNF-alpha, IL-1beta, IL-6, and IL-8.	lornoxicam	55-65	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	84-89
10450786-7	1999	RESULTS: In intact human cells, lornoxicam showed a balanced inhibition of COX-1/-2 exhibiting the lowest IC50 (0.005 microM/0.008 microM) of the large panel of NSAIDs tested.	lornoxicam	32-42	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	75-80
10450786-11	1999	In stimulated monocytic cells (THP-1), lornoxicam showed a marked inhibition of IL-6 formation (IC50 54 microM) while the formation ofTNF-alpha, IL-1beta and IL-8 was only moderately affected.	lornoxicam	39-49	GLI family zinc finger 2	Homo sapiens	31-36
10450786-11	1999	In stimulated monocytic cells (THP-1), lornoxicam showed a marked inhibition of IL-6 formation (IC50 54 microM) while the formation ofTNF-alpha, IL-1beta and IL-8 was only moderately affected.	lornoxicam	39-49	interleukin 6	Homo sapiens	80-84
10450786-12	1999	CONCLUSIONS: Of the panel of NSAIDs tested, lornoxicam was found to be the most potent balanced inhibitor of human COX-1/-2.	lornoxicam	44-54	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	115-120
10450786-13	1999	The equipotent COX-isoenzyme inhibition by lornoxicam is complemented by a marked inhibition of IL-6 production and of iNOS-derived NO formation.	lornoxicam	43-53	interleukin 6	Homo sapiens	96-100
10450786-13	1999	The equipotent COX-isoenzyme inhibition by lornoxicam is complemented by a marked inhibition of IL-6 production and of iNOS-derived NO formation.	lornoxicam	43-53	nitric oxide synthase 2	Homo sapiens	119-123
17657612-0	1997	Potent anti-inflammatory/analgesic effects of lornoxicam in comparison to other nsaids: a c-fos study in the rat.	lornoxicam	46-56	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	90-95
17657612-1	1997	This study evaluates the anti-inflammatory/analgesic effects of lornoxicam, a new non-steroidal anti-inflammatory drug, using the method of c-Fos protein immunoreactivity in the carrageenan model of inflammatory nociception in the rat.	lornoxicam	64-74	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	140-145
17657612-5	1997	Preadministered lornoxicam dose relatedly reduced the total number of c-Fos-LI neurons (regression coefficient r=0.79; p<0.001) with the strongest effect corresponding to the 75+/-2% reduction (p<0.001) for the highest dose of 9 mg/kg, and the 45+/-3% reduction (p<0.001) for the low dose of 0.3 mg/kg.	lornoxicam	16-26	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	70-75
17657612-8	1997	The lowes dose of lornoxicam (0.1 mg/kg iv) had a similar effect in both superficial and deep laminae, whereas the four higher doses (0.3, 1, 3 and 9 mg/kg iv) had a significantly stronger effect on the number of c-Fos-LI neurons in deep laminae as compared to that in superficial laminae.	lornoxicam	18-28	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	213-218
8857077-4	1996	The apparent affinity of lornoxicam was high for CYP2C9, but negligible for CYP3A4 and CYP2D6.	lornoxicam	25-35	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	49-55
8857077-5	1996	Inhibition of lornoxicam 5"-hydroxylation by CYP2C9 substrates and sulphaphenazole competitively and completely inhibited lornoxicam 5"-hydroxylation (Ki = 0.31 mu mol center dot l-1 as well as lornoxicam clearance (Ki = 0.33 mu mol center dot l-1), partial metabolic clearance (fm) = 0.95).	lornoxicam	14-24	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	45-51
8857077-5	1996	Inhibition of lornoxicam 5"-hydroxylation by CYP2C9 substrates and sulphaphenazole competitively and completely inhibited lornoxicam 5"-hydroxylation (Ki = 0.31 mu mol center dot l-1 as well as lornoxicam clearance (Ki = 0.33 mu mol center dot l-1), partial metabolic clearance (fm) = 0.95).	lornoxicam	122-132	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	45-51
8857077-5	1996	Inhibition of lornoxicam 5"-hydroxylation by CYP2C9 substrates and sulphaphenazole competitively and completely inhibited lornoxicam 5"-hydroxylation (Ki = 0.31 mu mol center dot l-1 as well as lornoxicam clearance (Ki = 0.33 mu mol center dot l-1), partial metabolic clearance (fm) = 0.95).	lornoxicam	122-132	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	45-51
8857077-6	1996	CONCLUSION: 5"-Hydroxylation appears to be the only cytochrome P-450 catalysed metabolic reaction of lornoxicam by human liver microsomes and this major in vivo biotransformation pathway is catalysed virtually exclusively by CYP2C9.	lornoxicam	101-111	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	225-231
8857077-2	1996	The reaction kinetics were characterised, the affinity of lornoxicam for three major human drug metabolising cytochrome P-450 isozymes (CYP2C9, CYP2D6 and CYP3A4) was determined, and inhibition of the reaction by known substrates (diclofenac, ibuprofen, mefenamic acid, phenytoin, tolbutamide and warfarin) and the prototype inhibitor (sulphaphenazole) of CYP2C9 was investigated.	lornoxicam	58-68	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	136-142
8857077-2	1996	The reaction kinetics were characterised, the affinity of lornoxicam for three major human drug metabolising cytochrome P-450 isozymes (CYP2C9, CYP2D6 and CYP3A4) was determined, and inhibition of the reaction by known substrates (diclofenac, ibuprofen, mefenamic acid, phenytoin, tolbutamide and warfarin) and the prototype inhibitor (sulphaphenazole) of CYP2C9 was investigated.	lornoxicam	58-68	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	144-150
8857077-2	1996	The reaction kinetics were characterised, the affinity of lornoxicam for three major human drug metabolising cytochrome P-450 isozymes (CYP2C9, CYP2D6 and CYP3A4) was determined, and inhibition of the reaction by known substrates (diclofenac, ibuprofen, mefenamic acid, phenytoin, tolbutamide and warfarin) and the prototype inhibitor (sulphaphenazole) of CYP2C9 was investigated.	lornoxicam	58-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	155-161
8857077-2	1996	The reaction kinetics were characterised, the affinity of lornoxicam for three major human drug metabolising cytochrome P-450 isozymes (CYP2C9, CYP2D6 and CYP3A4) was determined, and inhibition of the reaction by known substrates (diclofenac, ibuprofen, mefenamic acid, phenytoin, tolbutamide and warfarin) and the prototype inhibitor (sulphaphenazole) of CYP2C9 was investigated.	lornoxicam	58-68	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	356-362
34359151-6	2021	Within the lymphocyte population, the numbers of CD4+ T cells, gammadelta T cells, and B cells decreased significantly in blood after injection of camels with lornoxicam.	lornoxicam	159-169	LOW QUALITY PROTEIN: T-cell surface glycoprotein CD4	Camelus dromedarius	49-52
34359151-7	2021	In addition, injection of lornoxicam resulted in decreased abundance of major histocompatibility complex (MHC) class II molecules and increased abundance of the scavenger receptor CD163 on blood monocytes, indicating an anti-inflammatory phenotype of monocytes.	lornoxicam	26-36	scavenger receptor cysteine-rich type 1 protein M130	Camelus dromedarius	180-185